PRF Technologies Advances OcuRing-K to Phase I Support, Secures 71MW Solar SaaS Deal
PRF completed acquisition of DeepSolar and majority investment in LayerBio, advancing OcuRing™-K through IND-supporting activities with Phase I safety data and confirming multi-drug ocular delivery potential. DeepSolar launched Smart TDD, joined NVIDIA Connect, secured a 71MW Romanian SaaS contract and filed its first patent, ending 2025 with $4.1M cash.
1. Healthcare Platform Expansion
In August 2025 PRF acquired a majority stake in LayerBio to integrate its OcuRing™-K sustained-release ocular ring into the clinical pipeline. During 2025 the company completed IND-supporting tests, secured favorable Phase I safety results with no serious adverse events, and validated the platform’s ability to deliver multiple drug classes for broader ophthalmic applications.
2. DeepSolar Commercial Progress
Following its March acquisition of DeepSolar, PRF moved from pilot to initial commercial deployments by launching Smart TDD, joining the NVIDIA Connect Program, and signing a SaaS agreement for a 71 MW Romanian photovoltaic site. The unit also filed its first patent for micro-climate forecast modeling and engaged EDF Power Solutions Israel on due-diligence services.
3. Financial Position and Outlook
PRF ended 2025 with approximately $4.1 million in cash and equivalents and positive working capital of $2.0 million, while R&D expenses fell to $1.1 million from $11.7 million the prior year. Management plans disciplined investment across healthcare and solar analytics platforms to drive two independent value engines into 2026.